---
title: "Lepu Biopharma Signals 2025 Profit on Strong Oncology Sales and Licensing Gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278629108.md"
description: "Lepu Biopharma Co. Ltd. (HK:2157) has issued a profit alert, expecting a net profit of at least RMB200 million for the year ending December 31, 2025, a significant turnaround from a loss of RMB411 million in 2024. This improvement is attributed to strong sales of oncology products and increased licensing income. The company anticipates a one-off gain in 2025 due to a reclassification of an investment. Analysts currently rate the stock as a Hold with a price target of HK$4.50, advising caution until final results are confirmed."
datetime: "2026-03-10T22:38:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278629108.md)
  - [en](https://longbridge.com/en/news/278629108.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278629108.md)
---

# Lepu Biopharma Signals 2025 Profit on Strong Oncology Sales and Licensing Gains

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.

Lepu Biopharma has issued a positive profit alert, indicating it expects to post net profit attributable to shareholders of at least RMB200 million for the year ended 31 December 2025, compared with a loss of about RMB411 million in 2024. This anticipated turnaround reflects a strong pickup in revenue driven by domestic commercialization of key oncology products PUYOUHENG and newly approved MEIYOUHENG, along with expanding licensing income from deals such as the out-licensing of MRG007 and preclinical TCE assets CTM012 and CTM013.

The company also expects to record a one-off, non-recurring gain in 2025 after reclassifying an investment from an associate to a fair value investment following the loss of significant influence over the investee. While final audited results are pending and may differ from preliminary estimates, the guidance signals a substantial improvement in profitability and operational momentum, underscoring Lepu Biopharma’s strengthening commercial position in China’s oncology market and providing a potentially positive catalyst for shareholders and investors, albeit with a cautionary note regarding trading in its shares until final figures are released.

The most recent analyst rating on (HK:2157) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.

**More about Lepu Biopharma Co. Ltd. Class H**

Lepu Biopharma Co., Ltd. is a China-based biopharmaceutical company focused on oncology, developing and commercializing innovative anti-tumor drugs. Its portfolio includes products such as PUYOUHENG (pucotenlimab injection) and MEIYOUHENG (becotatug vedotin injection), and it also advances its pipeline through domestic commercialization and out-licensing of drug candidates, including preclinical T-cell engager assets.

**Average Trading Volume:** 6,985,576

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$8.27B

Learn more about 2157 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02157.HK](https://longbridge.com/en/quote/02157.HK.md)

## Related News & Research

- [Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Buys 5,000 Shares](https://longbridge.com/en/news/287244874.md)
- [BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models](https://longbridge.com/en/news/286973840.md)
- [08:13 ETContinuity Biosciences anuncia el primer ensayo clínico en humanos para el cáncer de páncreas](https://longbridge.com/en/news/287062849.md)
- [Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies](https://longbridge.com/en/news/286741077.md)
- [Hansoh Pharma Wins NMPA Breakthrough Status for Fourth-Gen Lung Cancer Drug](https://longbridge.com/en/news/287208778.md)